ArticleJournal of translational medicine2026
Doxorubicin induces ferroptosis in endometrial cancer by suppressing the MKK6/p38/CEBPB axis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDoxorubicin is a cornerstone chemotherapeutic agent. However, its role in ferroptosis and the underlying molecular mechanisms in endometrial cancer (EC) remain inadequately explored.
methodsWe integrated transcriptomic profiling, machine learning, and protein–protein interaction network analyses to identify ferroptosis-related regulators in EC. Functional validation was performed using CCK-8 and EdU assays, transmission electron microscopy, biochemical assays of ferroptosis markers, and Western blotting. Mechanistic studies included RNA sequencing, molecular docking, cellular thermal shift assays, and surface plasmon resonance. In vivo effects were evaluated in nude mouse xenograft models.
resultsBioinformatic analyses identified ferroptosis-related genes and highlighted a hub gene closely associated with drug sensitivity, with doxorubicin emerging as the agent most strongly linked to ferroptosis-related sensitivity. Doxorubicin markedly suppressed the proliferation of EC cells. This antiproliferative effect was partially reversed by ferrostatin-1. Morphological and biochemical analyses revealed features consistent with ferroptosis, including mitochondrial structural damage, increased lipid peroxidation, iron overload, and oxidative stress. Consistently, doxorubicin downregulated ferroptosis-associated proteins. Mechanistic studies demonstrated that doxorubicin binds directly to MKK6, thereby suppressing activation of the MKK6/P38/CEBPB signaling cascade. CEBPB positively regulates SLC7A11 expression and transactivates the SLC7A11 promoter in a motif-dependent reporter assay. CEBPB overexpression reverses both the anti-proliferative effects of doxorubicin and doxorubicin-induced ferroptosis in EC cells. In vivo, doxorubicin significantly reduced xenograft tumor growth while increasing ferroptosis-associated biochemical and molecular markers and inhibiting MKK6/P38 signaling.
conclusionOur findings uncover ferroptosis as a previously unrecognized mechanism of doxorubicin action in EC, establishing the MKK6/P38/CEBPB axis as a potential therapeutic target and opening new avenues for treatment optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.